TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03612323
Drug: Intra-ligamentary Piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment
Study: NCT03002454
Drug: 99mTc MDP Injection:neutron-bombardment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
Study: NCT03734068
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin is loaded to LIfePearl
Study: NCT02546960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
Study: NCT00579995
Drug: Oral N-Acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 milligrams (mg)
Study: NCT04515953
Drug: ND-340
Approvals — FDA: no, EMA: no, PMDA: no
Description: ND-340: Subjects will receive a single administration of ND-340 at the specified dose in each arm after TKA.
Study: NCT04515953
Drug: IV-PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-PCA: Intravenous patient-controlled analgesia (IV-PCA), morphine, will be administered in subjects of control group after TKA for postoperative pain management as standard practice.
Study: NCT01400932
Drug: GI148512
Approvals — FDA: no, EMA: no, PMDA: no
Description: GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
Study: NCT01400932
Drug: vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
Study: NCT01263015
Drug: Atripla placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo taken once daily on an empty stomach
Study: NCT01565395
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile preservative free 0.9% saline
Study: NCT03659058
Drug: silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: silymarin 140 three times daily
Study: NCT03659058
Drug: Antioxidants
Normalized name: E Complex with Antioxidants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
Study: NCT02736513
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive AZD9291 at a dose of 80 mg once daily.
Study: NCT02566356
Drug: Saline Nasal Spray
Normalized name: Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study: NCT00046930
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored.
Study: NCT04373473
Drug: PRIM-DJ2727
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727 capsules consists of lyophilized microbiota suspension from well-screened donors. Microbiota from three donors will be combined to make the product.
Study: NCT04373473
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
Study: NCT02482402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation solution placebo
Study: NCT04411537
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During neo-CRT: 625mg/m2 bid Monday-Friday per week
Study: NCT00391001
Drug: Taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: double-blind, placebo-controlled, adjunctive medication
Study: NCT01898156
Drug: BIW-8962
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached. BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.~Phase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops.
Study: NCT02472847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
Study: NCT03542851
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be presented as oral capsule.
Study: NCT00568113
Drug: acetylcysteine in arm 1
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy.
Study: NCT00121134
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once a day for 6 months
Study: NCT00121134
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twice daily for the first two days of every week for 6 months
Study: NCT00121134
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)
Study: NCT03909451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01363934
Drug: GC1113
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously.
Study: NCT00997620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
Study: NCT00154362
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00506194
Drug: OAD
Normalized name: Toad toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide-MR, Metformin, Glimepiride
Study: NCT03600454
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2µg/kg and propofol
Study: NCT03600454
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The level of puncture will be L4 - L5. 10 mg bupivacaine will be injected in the subarachnoid space, after spontaneous surge of cerebrospinal fluid
Study: NCT02257723
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
Study: NCT01048866
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
Study: NCT01048866
Drug: flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
Study: NCT01048866
Drug: acetaminophen 650mg
Normalized name: ACETAMINOPHEN 650MG TAB
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication to be taken as needed. Rescue medication was not blinded.
Study: NCT00722202
Drug: ERB-257
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02102152
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00554099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
Study: NCT00554099
Drug: Antibiotic for Diverticulitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
Study: NCT02922166
Drug: SRX246
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT02922166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT02761694
Drug: Vevorisertib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an oral dose every day or every other day.
Study: NCT00450736
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00907296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT00099281
Drug: YMB 1002
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02238340
Drug: ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02238340
Drug: dipirone
Normalized name: dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01916850
Drug: LX4211 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01916850
Drug: LX4211 800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01916850
Drug: LX4211 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00707746
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02787590
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02787590
Drug: Matched Placebo (for Simvastatin)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03770494
Drug: LY3405105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00316888
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01883427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo containing saline+glucose
Study: NCT05239221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution visually matching active medication
Study: NCT01386736
Drug: Placebo drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
Study: NCT01968577
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 40 mg before percutaneous coronary intervention
Study: NCT00983736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks.
Study: NCT02570243
Drug: High dose of Unfractionated Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated Heparin 100IU/Kg
Study: NCT02570243
Drug: Standard dose of Unfractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated heparin 50IU/Kg
Study: NCT04047420
Drug: TAF/EVG Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAF/EVG Insert (20/16 mg) administered rectally by study staff
Study: NCT03757130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to AMG 598 administered by subcutaneous injection
Study: NCT00700856
Drug: add-on sulphonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
Study: NCT02750384
Drug: DSM265 50% SDD granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose 400 mg
Study: NCT02750384
Drug: DSM265 25% SDD powder for suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose 400 mg
Study: NCT02608450
Drug: CB-03-01 cream, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
Study: NCT02608450
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
Study: NCT00170989
Drug: valsartan plus hydrochlorothiazide
Normalized name: hydrochlorothiazide / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00625612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
Study: NCT04589143
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets of placebos at a dose of 25-50 mg/d for 8 weeks
Study: NCT02609945
Drug: CVT-427 (zolmitriptan inhalation powder),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
Study: NCT01840254
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00533650
Drug: MK0429
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02576860
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel
Study: NCT03727412
Drug: Drugs, Generic (Naprosyn)
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
Study: NCT03727412
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
Study: NCT00649675
Drug: Meloxicam Tablets 15 mg
Normalized name: meloxicam Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg, single dose fed
Study: NCT00649675
Drug: Mobic® Tablets 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg, single dose fed
Study: NCT00714519
Drug: Xenaderm® Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical, BID or as needed
Study: NCT00714519
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical, BID or as needed
Study: NCT02910167
Drug: Hyoscine n-butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine n-butylbromide 10 mg
Study: NCT00149942
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02642432
Drug: ABT-493/ABT-530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-493 coformulated with ABT-530
Study: NCT00477269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00260858
Drug: Test Meal: Reference food (glucose or white bread)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00260858
Drug: Test Meal: Pirate's Booty
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00260858
Drug: Test Meal: Ceaprove wafer
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00087451
Drug: AP23573
Approvals — FDA: no, EMA: no, PMDA: no
Description: ridaforolimus
Study: NCT03762382
Drug: TFV/LNG IVR
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.
Study: NCT03762382
Drug: TFV IVR
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.
Study: NCT03762382
Drug: Placebo IVR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.
Study: NCT04445623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of placebo daily for 15 days
Study: NCT02225912
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03780959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered twice weekly by subcutaneous injection
Study: NCT03689244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets without active compound
Study: NCT01276821
Drug: L-Epinephrine and Normal Saline (0.9%)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline
Study: NCT01276821
Drug: L-Epinephrine and Hypertonic Saline (3%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline
Study: NCT00595933
Drug: mouth spray
Normalized name: Moi-Stir Dry Mouth Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray mouth with mouth spray 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
Study: NCT00595933
Drug: mouth spray
Normalized name: Moi-Stir Dry Mouth Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
Study: NCT01363583
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-1.5 ml/hour during 4 days
Study: NCT03426631
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule 30 minutes before sleep
Study: NCT03426631
Drug: DAW1033B2 oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAW1033B2 capsule 30 minutes before sleep
Study: NCT02018874
Drug: LY2780301
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :~* Dose level -1: 300 mg Q.D.~* Dose level -0.5: 400 mg Q.D.~* Dose level 1: 400 mg Q.D.~* Dose level 1.5: 500 mg Q.D.~* Dose level 2 : 500 mg Q.D.
Study: NCT01195688
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral doses given to 2 subjects per dose group
Study: NCT03033342
Drug: Oral single doses of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of placebo to match MRX-4
Study: NCT03033342
Drug: Oral multiple doses of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo given twice daily for 10 days to match the oral MRX-4
Study: NCT03322215
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablet 500 - 1,250 mg/m2 twice Daily, for 2 weeks followed by 1 week of rest.
Study: NCT01910870
Drug: Metronomic Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
Study: NCT01238978
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000514
Drug: chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02382848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin-matched placebo pill
Study: NCT00865085
Drug: CelexaTM 40 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
Study: NCT01595581
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of testosterone administration beginning 2 weeks before ACL surgery
Study: NCT01595581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks of saline administration beginning 2 weeks before ACL surgery
Study: NCT01713556
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00473603
Drug: lipid/heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: to perform an i.v. lipid heparin infusion infusion for 4 h
Study: NCT02426151
Drug: BEPO-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEPO-A (Bioreactor manufacturing process)
Study: NCT02426151
Drug: REPO-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: REPO-A (Roller bottle manufacturing process)
Study: NCT03474081
Drug: FF/UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single inhaler triple therapy of FF/UMEC/VI will be provided via ELLIPTA DPI. FF/UMEC/VI will be available as dry white powder with dosing strengths of 100/25/62.5 mcg per blister.